Navigation Links
Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful complication of shingles, affects approximately 200,000 people a year in the US alone. The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with PHN. Solace anticipates having results from the study in the second half of 2009.

SLC022 is an orally administered glial cell modulator that has shown efficacy in well-established preclinical pain models. Glial cells represent an important new target for the treatment of chronic pain based on their active role in neuronal pain signaling.

"The initiation of this study is another important milestone for Solace in our drive to discover and develop innovative treatments for pain," said Dr. Eliot Forster, Solace's Chief Executive Officer. "Our confidence in SLC022 is underpinned by a large body of prior preclinical and clinical data generated during the compound's previous development in a non-pain indication. We believe these data lower the development risk and enhance the opportunity for a favorable clinical profile."

Solace's advancement of SLC022 caps a year of significant progress. In 2008, Solace expanded its glial cell modulator program by identifying next-generation, novel leads with attractive drug properties. The company made equally rapid progress in optimizing inhibitors of the enzyme GTP cyclohydrolase 1 (GCH1), a key target within the BH4 synthesis pathway, and in identifying additional promising drug targets.

Solace Pharmaceuticals also established a two-year collaboration with Professor Keith Channon, MD FRCP, of the Department of Cardio
'/>"/>

SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
8. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good chance ... Gionfriddo , about her now 20-month-old son, Kaiba. "At ... would take it and run with it." They ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, Inc., ... of viral infections, today announced that it has initiated ... its investigational, once daily, oral therapy for the treatment ... HCV-infected patients and is designed to assess both the ... is a first-in-class drug for the treatment of chronic ...
(Date:5/23/2013)... ALBUQUERQUE, N.M. , May 23, 2013  Net ... in the telemedicine market, announced today the company has ... a telemedicine staffing company based in Huntsville, ... agency that specializes in the staffing and recruitment of ... upon completion of the final agreement, which is expected ...
Breaking Medicine Technology:Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... Dune Medical Devices, Inc. today announced that the ... for filing the company,s Pre-Market Approval (PMA) application ... that the PMA application was sufficiently complete and ... MarginProbe represents a breakthrough technology that may offer ...
... WASHINGTON, May 16, 2011 During Older ... encourages America,s seniors to connect with their pharmacist to ... and available wellness opportunities. As the most accessible health ... to discuss many of the issues that arise due ...
Cached Medicine Technology:FDA Formally Accepts Dune Medical's MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status 2APhA Encourages Seniors to Connect with Their Pharmacist to Increase Wellness and Medication Knowledge 2APhA Encourages Seniors to Connect with Their Pharmacist to Increase Wellness and Medication Knowledge 3
(Date:5/23/2013)... May 23, 2013 Today, Zane Benefits, ... mandate . Zane Benefits, which provides comprehensive and flexible ... leader in defined contribution plans and ... a common question from employees is “does my employer ... website, not necessarily. The health care reform law, called ...
(Date:5/23/2013)... Mann HealthDay Reporter , , THURSDAY, May 23 ... take to help treat hip and knee osteoarthritis may ... for developing glaucoma, a small new study of older ... an increase of intraocular pressure (IOP) or pressure inside ... leading causes of blindness. In the ...
(Date:5/23/2013)... journal Science published an article about bexarotene ... an important starting point for further Alzheimer,s research. The ... at VIB and KU Leuven in collaboration with ... and scientists at Janssen Pharmaceutica, Beerse, also tested this ... results were different, as were those of two American ...
(Date:5/23/2013)... about to be tested in a clinical trial by ... for Alzheimer,s disease has failed to work with the ... according to results of a study by University of ... neuroscience affiliated with the Evelyn F. and William L. ... the importance of verifying promising research results before investing ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Dr. ... her new charitable organization in Orange County, OCCares , ... in Orange County. The event details are as follows: ... Orangewood Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 ... pop crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... was more rapid afterward, study finds , , TUESDAY, Oct. ... education seems to delay the onset of dementia, but ... a new study finds. , The findings confirm ... with more education have some kind of brain "reserve" ...
... dont dispute the important role that diet and activity ... eating habits and a less active lifestyle fully explain ... That question has led some researchers to ask whether ... In the October issue of Mayo Clinic Proceedings, researcher ...
... calls for greater collaboration across Europe on research in ... in improved and cost-effective healthcare, the ESF says, but ... and industry if Europe is to realise the full ... The call comes in a new ESF Science Policy ...
... LA JOLLA, Calif., Oct. 23 Immunosyn,Corporation (OTC Bulletin ... as the company,s Chief Executive Officer, President and,board member. ... role at Immunosyn and help,shape the company,s success. I ... life for millions of people who suffer from painful ...
... of fatigue might find some relief through regular exercise ... a new review. , Fatigue is one of ... those undergoing treatment with radiation and chemotherapy. According to ... cancer treatment experience fatigue that can range from mild ...
... McKusick-Nathans Institute of Genetic Medicine today are releasing newly ... Hopkins data, coordinated with a similar data release from ... hereditary factors and speed the understanding of autism by ... look to date at the genetic variation patterns in ...
Cached Medicine News:Health News:Dementia in More Educated Hits Later But Harder 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 3Health News:Improving Europe's image 2Health News:Immunosyn Corporation Names Stephen Ferrone as CEO 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 3Health News:Hopkins researchers release genome data on autism 2
... Hold & Support A Dropping Lens To Safely ... Phacoemulsification To ,Continue. Can Support Multiple ... Cyclodialysis Spatula To Reach Into The ... Lens Fragments With One Instrument. ,A 23g ...
... In-Line Footplates Are Turned 90 Degrees ... Diamond Blade While Incising Tissue. ,Special Mirror-Polished ... Depth Penetration.,Pre-Set Blade Extension Settings Of ... And Full Extension.,1mm Wide Snub Nose ...
... 0.1mm Pierce Tip Opening Is Designed ... The Need For A Separate Cystotome. The 11mm ... Without Elevating The Incision.,The Distal Jaws Have Platforms, ... To Prevent Inadvertent Pick Up Of Iris. The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: